Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently sold a significant portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Hohl sold a total of 5,250 shares of common stock on November 27, 2024. The shares were sold at prices ranging from $24.7795 to $25.3755, resulting in total proceeds of approximately $130,688. The transaction occurred near the stock's current trading range, with ELVN shares showing remarkable strength, gaining over 110% in the past year. The company, currently valued at $1.2 billion, maintains a "GOOD" financial health score according to InvestingPro analysis.
Additionally, Hohl exercised stock options to acquire 5,250 shares at a price of $2.48 per share on the same day. This transaction was executed as part of a pre-established trading plan under Rule 10b5-1, which Hohl adopted on June 26, 2023. Following these transactions, Hohl's direct ownership in the company stands at 168,556 shares. Analysts maintain a bullish outlook on ELVN, with price targets ranging from $33 to $40 per share. Get access to more exclusive insights and detailed financial metrics with InvestingPro, which offers additional ProTips about the company's financial position and growth prospects.
The sales were conducted in multiple trades, and Hohl has committed to providing detailed information on the individual sale prices upon request by the SEC, the company, or its shareholders.
In other recent news, Enliven Therapeutics has been in the spotlight following strong trial data and positive ratings from several analyst firms. Baird increased the stock's price target to $40 from $32, maintaining an Outperform rating, following Enliven's recent third-quarter 2024 results and promising data from ongoing trials. This revision reflects higher peak sales assumptions for the company's ELVN-001 drug, which has shown compelling results in treating Chronic Myeloid Leukemia (CML).
Furthermore, Jones Trading assigned a Buy rating and set a price target of $36.00, highlighting the development of potentially top-tier drugs for CML and HER2-positive breast cancer. They estimated probability-adjusted peak sales of approximately $800 million worldwide for ELVN-001 by 2036.
H.C. Wainwright maintained a Buy rating with a steady price target of $37.00, following the presentation of updated Phase 1 results for ELVN-001, which showed promising outcomes in treating CML. Mizuho (NYSE:MFG) reaffirmed its Outperform rating and a $39.00 price target, following the company's presentation of updated Phase 1a data for ELVN-001, demonstrating a consistent major molecular response rate and a clean safety profile.
TD Cowen also maintained its Buy rating, following the presentation of updated clinical trial data, showing a 44.4% Major Molecular Response at 24 weeks in 8 out of 18 patients. These developments underscore Enliven Therapeutics' progress in the biotech industry, with an emphasis on the company's robust financial health and strong trial prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.